Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

1.500 -0.100 (-6.25%)
Delayed Quote Updated: 3:50 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,905
Open 1.630
Bid (Size) 1.500 (100)
Ask (Size) 1.540 (200)
Prev. Close 1.600
Today's Range 1.475 - 1.670
52wk Range 1.500 - 12.60
Shares Outstanding 833,683
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Strategic Review to Maximize Value of Oncology Portfolio
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Safety Results for TTX-MC138 at ESMO Congress 2026
Via Investor Brand Network

Performance

52-Week Range 88.1% below 52-week high
1.500
1.5052W Low 12.6052W High
1 Week 21.5% below 1-week high
1.501W Low 1.911W High

TransCode Therapeutics, Inc. - Common Stock (RNAZ) traded between $1.50 and $12.60 over the past 52 weeks and last traded at $1.50, 88.1% below its 52-week high. Over the past week it ranged between $1.50 and $1.91.

Past 12 Months
-13.3%
-14.8%
-64.7%
-80.1%
-79.7%
-84.2%
1W -$0.23
1M -$0.26
3M -$2.75
6M -$6.02
YTD -$5.90
1Y -$8.00

RNAZ was -84.2% over the past year, -80.1% over six months, -79.7% year to date, -13.3% in the last week.

12 Months vs Market
RNAZ
-84.2%
DIA
+9.6%
SPY
+9.0%
QQQ
+5.2%
IWM
+12.8%

Over the past 12 months RNAZ returned -84.2% versus DIA (Dow) +9.6%, SPY (S&P 500) +9.0%, QQQ (Nasdaq 100) +5.2% and IWM (Russell 2000) +12.8%.

Volume & Liquidity 0.37× 3-mo avg
Today 19,905 3-mo avg 53.6K
1W
21.7K
1M
33.2K
3M
53.6K
6M
58.0K
YTD
108.3K
1Y
94.3K

RNAZ most recently traded 19,905 shares against a 3-month average daily volume of 53.6K.

More News

Read More
NetworkNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Present Updated Phase 1a TTX-MC138 Clinical Data at ESMO Congress 2026
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Updated Phase 1a Data for TTX-MC138 in Advanced Solid Tumors
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Expands Global Patent Portfolio for RNA-Based Cancer Therapies
Via Investor Brand Network
Topics Intellectual Property
News headline image
Join Today's Live Investor Webinar with TransCode Therapeutics
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
NetworkNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Names John Tattory Interim CFO Following Tom Fitzgerald Retirement
Via Investor Brand Network
Topics Retirement
News headline image
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports TTX-MC138 Survival Benefit in Preclinical Breast Cancer Bone Metastasis Study
Via Investor Brand Network
News headline image
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Host First R&D Webcast Highlighting Phase 2a Oncology Program
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Results for TTX-MC138 and Advances Program Toward Phase 2a
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Scientific Advisory Board Chair, Signs Research Agreement With Michigan State University
Via Investor Brand Network
MissionIRNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Up to $20 Million Financing Agreement
Via Investor Brand Network
BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates
Via Investor Brand Network
BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Announces Publication On Tumor-Selective RIG-I Immunotherapy Approach
Via Investor Brand Network
BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors
Via Investor Brand Network
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation
Via Investor Brand Network

Frequently Asked Questions

Is TransCode Therapeutics, Inc. - Common Stock publicly traded?
Yes, TransCode Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does TransCode Therapeutics, Inc. - Common Stock trade on?
TransCode Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TransCode Therapeutics, Inc. - Common Stock?
The ticker symbol for TransCode Therapeutics, Inc. - Common Stock is RNAZ on the Nasdaq Stock Market
What is the current price of TransCode Therapeutics, Inc. - Common Stock?
The current price of TransCode Therapeutics, Inc. - Common Stock is 1.500
When was TransCode Therapeutics, Inc. - Common Stock last traded?
The last trade of TransCode Therapeutics, Inc. - Common Stock was at 11/05/26 03:50 PM ET
What is the market capitalization of TransCode Therapeutics, Inc. - Common Stock?
The market capitalization of TransCode Therapeutics, Inc. - Common Stock is 1.25M
How many shares of TransCode Therapeutics, Inc. - Common Stock are outstanding?
TransCode Therapeutics, Inc. - Common Stock has 1M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.